Valeritas Holdings Inc (VLRX) 6.0000 $VLRX Vale
Post# of 273254
Posted On: 09/22/2016 1:11:05 AM
Valeritas Holdings Inc (VLRX) 6.0000 $VLRX
Valeritas to Present at the Rodman & Renshaw Global Investment Conference
GlobeNewswire - Tue Sep 06, 7:10AM CDT
Valeritas Holdings, Inc. (OTCQB:VLRX) announced today that John Timberlake, President and Chief Executive Officer is scheduled to present at the Rodman & Renshaw 18 Annual Global Investment Conference.
Valeritas Appoints Erick J. Lucera as Chief Financial Officer
GlobeNewswire - Tue Aug 16, 7:00AM CDT
Valeritas Holdings, Inc. (OTCQB:VLRX) announced today the appointment of Erick J. Lucera as the Company's Chief Financial Officer, effective August 29, 2016. Mr. Lucera will be based primarily in the Company's Shrewsbury, Massachusetts office.
V-Go(R) Data and Clinical Benefit Discussed During Panel Presentation on Insulin Therapy and Delivery at AADE 2016
GlobeNewswire - Mon Aug 15, 7:00AM CDT
Valeritas Holdings, Inc. (OTCQB:VLRX) announced today that clinical data demonstrating the clinical benefits of V-Go, the Company's disposable insulin delivery device designed with the needs of the patient with Type 2 diabetes in mind, were highlighted in a presentation at the American Academy of Diabetes Educators (AADE) annual meeting at the San Diego Convention Center in San Diego, CA. In addition, demonstrations to clinicians on V-Go's ease of use were available from Aug. 12 to 14 at the Company's booth, #437, in the Exhibition Hall at the convention center.
Valeritas Reports Second Quarter 2016 Financial Results
GlobeNewswire - Wed Aug 10, 3:01PM CDT
Conference Call and Webcast Today, August 10, at 4:30 p.m. EDT
Valeritas to Present at the Wedbush PacGrow Healthcare Conference
GlobeNewswire - Thu Jul 28, 7:01AM CDT
Valeritas Holdings, Inc. (OTCQB:VLRX) announced today that John Timberlake, President and Chief Executive Officer is scheduled to present at the Wedbush PacGrow Healthcare Conference.
Valeritas Appoints David Lewis as Vice President of Marketing
GlobeNewswire - Thu Jun 23, 7:00AM CDT
Valeritas Holdings, Inc. (OTCQB:VLRX) announced today that David Lewis has been named Vice President of Marketing. Mr. Lewis joins the Company with extensive experience successfully building chronic therapeutic brands including several current market-leading brands in diabetes. Notably, Mr. Lewis led the launch of Januvia, one of Merck & Company's first and most successful new product launches in the U.S. diabetes market, and then went on to lead marketing for the global launch of AstraZeneca and Bristol-Myers Squibb's Forxiga for the treatment of type-2 diabetes.
MRK: 62.70 (+0.76), BMY: 55.93 (+0.37)
Valeritas Announces Positive Results in Four Studies on V-Go(R) Disposable Insulin Delivery Device at ADA 2016
GlobeNewswire - Mon Jun 13, 7:07AM CDT
Valeritas Holdings, Inc. (OTCQB:VLRX) announced today positive results from four studies discussing the clinical and cost benefits of the company's lead product the V-Go Disposable Insulin Delivery device. The data were presented this past weekend in four posters at the American Diabetes Association (ADA), 76 Scientific Sessions in New Orleans, LA, June 10-14, 2016.
Valeritas Announces Retrospective Analysis of the V-Go(R) Disposable Insulin Delivery Device Published Online in Drugs-Real World Outcomes, an International, Peer-Reviewed Journal
GlobeNewswire - Mon Jun 06, 7:59AM CDT
Valeritas Holdings, Inc. (OTCQB:VLRX) announced today the online publication of a retrospective analysis of the V-GoDisposable Insulin Delivery device in Drugs-Real World Outcomes, an international, peer-reviewed journal. The title of the article is The Clinical and Economic Impact of the V-Go Disposable Insulin Delivery Device for Insulin Delivery in Patients with Poorly Controlled Diabetes at High Risk. The article was authored by Dr. Rosemarie Lajara, endocrinologist, Diabetes Centers of America, Plano, TX; Carla Nikkel, Associate Director, Medical Affairs at Valeritas, Bridgewater, NJ and Scott Abbott, Associate Director, Medical Affairs at Valeritas, Bridgewater, NJ.
Valeritas Presents Positive Results of Five Real-World Studies of the V-Go® Disposable Insulin Delivery Device at AACE 2016
PR Newswire - Fri May 27, 8:15AM CDT
Valeritas Holdings, Inc. (OTCQB: VLRX) announced today the positive results of five retrospective analyses of the clinical and cost benefits of the company's lead product, the V-Go® Disposable Insulin Delivery device. The data were disclosed this past weekend in five posters presented at the American Association of Clinical Endocrinologists' (AACE) 25th Annual Scientific and Clinical Conference in Orlando, Florida, May 25 - 29, 2016.
Valeritas Completes Alternative Public Offering and Raises Gross Proceeds of $25.2 Million
PR Newswire - Wed May 04, 6:00AM CDT
Valeritas Holdings, Inc. (OTCQB: VLRX) announced today its successful completion of an alternative public offering (APO). This was accomplished via a reverse merger of its wholly owned operating company, Valeritas, Inc. and a private placement of approximately 5 million shares of its unregistered common stock at $5.00 per share.
Valeritas to Present at the Rodman & Renshaw Global Investment Conference
GlobeNewswire - Tue Sep 06, 7:10AM CDT
Valeritas Holdings, Inc. (OTCQB:VLRX) announced today that John Timberlake, President and Chief Executive Officer is scheduled to present at the Rodman & Renshaw 18 Annual Global Investment Conference.
Valeritas Appoints Erick J. Lucera as Chief Financial Officer
GlobeNewswire - Tue Aug 16, 7:00AM CDT
Valeritas Holdings, Inc. (OTCQB:VLRX) announced today the appointment of Erick J. Lucera as the Company's Chief Financial Officer, effective August 29, 2016. Mr. Lucera will be based primarily in the Company's Shrewsbury, Massachusetts office.
V-Go(R) Data and Clinical Benefit Discussed During Panel Presentation on Insulin Therapy and Delivery at AADE 2016
GlobeNewswire - Mon Aug 15, 7:00AM CDT
Valeritas Holdings, Inc. (OTCQB:VLRX) announced today that clinical data demonstrating the clinical benefits of V-Go, the Company's disposable insulin delivery device designed with the needs of the patient with Type 2 diabetes in mind, were highlighted in a presentation at the American Academy of Diabetes Educators (AADE) annual meeting at the San Diego Convention Center in San Diego, CA. In addition, demonstrations to clinicians on V-Go's ease of use were available from Aug. 12 to 14 at the Company's booth, #437, in the Exhibition Hall at the convention center.
Valeritas Reports Second Quarter 2016 Financial Results
GlobeNewswire - Wed Aug 10, 3:01PM CDT
Conference Call and Webcast Today, August 10, at 4:30 p.m. EDT
Valeritas to Present at the Wedbush PacGrow Healthcare Conference
GlobeNewswire - Thu Jul 28, 7:01AM CDT
Valeritas Holdings, Inc. (OTCQB:VLRX) announced today that John Timberlake, President and Chief Executive Officer is scheduled to present at the Wedbush PacGrow Healthcare Conference.
Valeritas Appoints David Lewis as Vice President of Marketing
GlobeNewswire - Thu Jun 23, 7:00AM CDT
Valeritas Holdings, Inc. (OTCQB:VLRX) announced today that David Lewis has been named Vice President of Marketing. Mr. Lewis joins the Company with extensive experience successfully building chronic therapeutic brands including several current market-leading brands in diabetes. Notably, Mr. Lewis led the launch of Januvia, one of Merck & Company's first and most successful new product launches in the U.S. diabetes market, and then went on to lead marketing for the global launch of AstraZeneca and Bristol-Myers Squibb's Forxiga for the treatment of type-2 diabetes.
MRK: 62.70 (+0.76), BMY: 55.93 (+0.37)
Valeritas Announces Positive Results in Four Studies on V-Go(R) Disposable Insulin Delivery Device at ADA 2016
GlobeNewswire - Mon Jun 13, 7:07AM CDT
Valeritas Holdings, Inc. (OTCQB:VLRX) announced today positive results from four studies discussing the clinical and cost benefits of the company's lead product the V-Go Disposable Insulin Delivery device. The data were presented this past weekend in four posters at the American Diabetes Association (ADA), 76 Scientific Sessions in New Orleans, LA, June 10-14, 2016.
Valeritas Announces Retrospective Analysis of the V-Go(R) Disposable Insulin Delivery Device Published Online in Drugs-Real World Outcomes, an International, Peer-Reviewed Journal
GlobeNewswire - Mon Jun 06, 7:59AM CDT
Valeritas Holdings, Inc. (OTCQB:VLRX) announced today the online publication of a retrospective analysis of the V-GoDisposable Insulin Delivery device in Drugs-Real World Outcomes, an international, peer-reviewed journal. The title of the article is The Clinical and Economic Impact of the V-Go Disposable Insulin Delivery Device for Insulin Delivery in Patients with Poorly Controlled Diabetes at High Risk. The article was authored by Dr. Rosemarie Lajara, endocrinologist, Diabetes Centers of America, Plano, TX; Carla Nikkel, Associate Director, Medical Affairs at Valeritas, Bridgewater, NJ and Scott Abbott, Associate Director, Medical Affairs at Valeritas, Bridgewater, NJ.
Valeritas Presents Positive Results of Five Real-World Studies of the V-Go® Disposable Insulin Delivery Device at AACE 2016
PR Newswire - Fri May 27, 8:15AM CDT
Valeritas Holdings, Inc. (OTCQB: VLRX) announced today the positive results of five retrospective analyses of the clinical and cost benefits of the company's lead product, the V-Go® Disposable Insulin Delivery device. The data were disclosed this past weekend in five posters presented at the American Association of Clinical Endocrinologists' (AACE) 25th Annual Scientific and Clinical Conference in Orlando, Florida, May 25 - 29, 2016.
Valeritas Completes Alternative Public Offering and Raises Gross Proceeds of $25.2 Million
PR Newswire - Wed May 04, 6:00AM CDT
Valeritas Holdings, Inc. (OTCQB: VLRX) announced today its successful completion of an alternative public offering (APO). This was accomplished via a reverse merger of its wholly owned operating company, Valeritas, Inc. and a private placement of approximately 5 million shares of its unregistered common stock at $5.00 per share.
(0)
(0)Scroll down for more posts ▼